This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ACADIA Pharmaceuticals Inc. (ACAD)
Q2 2012 Earnings Call
August 8, 2012 5:00 pm ET
Thomas H. Aasen – Treasurer, Chief Financial & Business Officer
Uli Hacksell – President, Chief Executive Officer & Director
Roger M. Mills – Executive Vice President-Development
Charles C. Duncan – JMP Securities LLC
Bert C. Hazlett – ROTH Capital Partners LLC
Jason Napodano – Zacks Investment Research, Inc.
Juan Sanchez – Ladenburg Thalmann Securities
Brian William Lian – SunTrust Robinson Humphrey
George B. Zavoico – McNicoll, Lewis & Vlak LLC
Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals’ Second Quarter 2012 Financial Results Conference Call. My name is Dianna, and I will be the coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. (Operator Instructions)
I would now like to turn the presentation over to Tom Aasen, Executive Vice President and Chief Financial Officer at ACADIA. Please proceed.
Thank you. Good afternoon and welcome to ACADIA Pharmaceuticals second quarter 2012 conference call. This call is being recorded and an archived copy will be available on our website at www.acadia-pharm through August 22nd of this year.
Joining me on the call today from ACADIA are Dr. Uli Hacksell, our Chief Executive Officer; and Dr. Roger Mills, our Executive Vice President of Development. We will begin our call today with some introductory remarks by Uli, and then I’ll briefly comment on our financial results for the second quarter. After this Roger and Uli will provide you with an update on our development programs and we’ll then open the floor to your questions.